Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2024 | The urgency of diagnosing and treating patients with Castleman disease

Karthik Ramasamy • 28 Apr 2024
BSH 2024
Castleman Disease Rare Diseases Antibodies Siltuximab

Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, briefly comments on a talk centered around the urgency of treating patients with idiopathic multicentric Castleman disease (iMCD) at the time of diagnosis. Using siltuximab therapy at the time of diagnosis can aid in symptom relief and induce remission to improve patient outcomes. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Karthik Ramasamy

2:13
Frontline treatment of transplant eligible patients with myeloma: current approach & future changes
Karthik Ramasamy • 28 Apr 2024
1:33
Post-hoc analysis of TOURMALINE-MM1 data while adjusting for subsequent therapies
Karthik Ramasamy • 28 Apr 2024
1:14
Using MRD to accelerate drug approval in multiple myeloma
Karthik Ramasamy • 28 Apr 2024
1:15
Using MRD to guide treatment decisions in myeloma
Karthik Ramasamy • 28 Apr 2024

Related Videos

2:24
Primary prevention against atherosclerosis in patients with hemophilia
Beverley Hunt • 29 Apr 2024
1:40
The current therapeutic landscape for indolent and advanced systemic mastocytosis
Deepti Radia • 29 Apr 2024
0:52
The unmet needs that remain for patients with systemic mastocytosis
Deepti Radia • 29 Apr 2024
2:45
Continuity of care for patients with hematological predispositions to AML
Anupama Rao • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals